Lymphoma hub
@lymphomahub.bsky.social
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia.
New publication 📝 BRUIN CLL-314 phase III results, published in the Journal of Clinical Oncology, show that pirtobrutinib demonstrated noninferior ORR to ibrutinib (87.0% vs 78.5%; p < 0.0035) in TN or R/R BTKi-naïve CLL/SLL. Learn more: https://loom.ly/jLklx8s #leusm #lymsm #MedNews #MedEd
New publication📝 5-year follow-up results from the phase II JULIET trial, published in the Journal of Clinical Oncology, show tisagenlecleucel had an ORR of 53.0% in patients with R/R LBCL, with the median DoR not reached. Learn more: https://loom.ly/rC-uX7Y #lymphoma #lymsm #MedNews #MedEd
New publication📝HOVON 158/NEXT STEP results, published in The Lancet Haematology, show MRD-guided ibrutinib + obinutuzumab intensification after ibrutinib + venetoclax achieved 60% CR/CRi with BM uMRD4 at 3 months in TN CLL. Learn more: https://loom.ly/iVvKXk4 #lymphoma #lymsm #MedNews #MedEd
🚨News 🚨 Health Canada approves pirtobrutinib, a non-covalent BTKi, for the treatment of patients with R/R MCL and CLL/SLL who have received ≥2 prior lines of therapy. Read more: https://loom.ly/jvX61wU #lymsm #leusm #MedEd #MedNews
New publication📝Phase III inMIND data, published in Lancet, show tafasitamab + lenalidomide + rituximab significantly improved median PFS vs placebo (22.4 vs 13.9 months; p < 0.0001) in R/R FL. Learn more: https://loom.ly/uiZeapw #lymsm #lymphoma #MedNews #MedEd
New publication📝Results from the CLL17 trial, published in @NEJM, show noninferior 3-year PFS with fixed-duration venetoclax + obinutuzumab or venetoclax + ibrutinib vs continuous ibrutinib in previously untreated CLL. Learn more: https://loom.ly/iVvKXk4 #lymphoma #lymsm #MedNews #MedEd
The FDA has removed the REMS requirements for approved CAR T-cell therapies. Check out our visual abstract summarizing these changes: https://loom.ly/DAbLNQs #lymsm #Lymphoma #MedNews #MedEd
🚨 News 🚨 The FDA clears an IND application for APG-3288, a novel BTK-targeted protein degrader, for the treatment of relapsed/refractory B-cell malignancies. Read more: https://loom.ly/_qG9hog #Lymphoma #Lymsm #MedNews
Read our latest overview of class effects, treatment guidelines, and real-world evidence for BTKi in patients with CLL: https://loom.ly/Zlwwbfs #leusm #lymsm #MedEd #MedNews
In our latest podcast, Joshua Brody shared his key highlights in lymphoma and CLL from #ASH25. Listen here: https://loom.ly/a0CqZnU #lymsm #lymphoma #MedEd
Joshua Brody shared his key highlights in lymphoma and CLL from #ASH25. Watch here: https://loom.ly/OSJsgR8 #lymsm #lymphoma #MedEd
Alexey Danilov discussed results from the phase I study of bexobrutideg, a novel BTK degrader, in patients with R/R CLL, which were presented at #ASH25. Watch here: https://loom.ly/M45g2y4 #lymsm #leusm #MedEd
Susan O’Brien, @ChaoCompCancer @UCIrvineHealth, discussed results from the CAPTIVATE trial of ibrutinib + venetoclax in patients with CLL. Watch the full video here: https://loom.ly/F7tWpYY #leusm #lymsm #MedNews #MedEd
🚨 NEWS 🚨 FDA approves a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial. Read more: https://loom.ly/p7QgFmU #lymphoma #lymsm #MedNews #MedEd
🚨 NEWS 🚨 Japan's Ministry of Health, Labour and Welfare approves tafasitamab in combination with rituximab + lenalidomide for adult patients with R/R FL, based on data from the phase III inMIND trial. Read more: https://loom.ly/n4AYOKI #lymphoma #lymsm #mednews
The Lymphoma Hub was pleased to speak with Alexey Danilov at #ASH25. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL? Watch the full video here: https://loom.ly/M45g2y4 #lymsm #leusm #MedEd
What are the class effects, treatment guidelines, and real-world evidence for BTKi in patients with CLL? Read our latest article here: https://loom.ly/Zlwwbfs #leusm #lymsm #MedEd #MedNews
In our latest podcast, Alexey Danilov discusses results from the ongoing phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL, presented at #ASH25 Listen here: https://loom.ly/BLdORcI #lymsm #leusm #MedEd
Catch up on the latest developments in aggressive B-cell NHL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/POS6cqk #lymsm #leusm #MedicalCongress
Catch up on the latest developments in indolent and mantle cell NHL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/FTOLNe8 #lymsm #leusm #MedicalCongress
The Lymphoma Hub was pleased to speak with Joshua Brody at #ASH25. We asked, What were your key highlights in lymphoma and CLL from the meeting? Watch here: https://loom.ly/OSJsgR8 #lymsm #lymphoma #MedEd
What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL? The Lymphoma Hub was pleased to speak to Susan O’Brien about the latest results from the CAPTIVATE trial. Listen here: https://loom.ly/EUxV_Fs #leusm #lymsm #MedNews #MedEd
Catch up on the latest developments in CLL/SLL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/gh3vlu8 #lymsm #leusm #MedicalCongress
🚨 NEWS 🚨 The European Commission has approved tafasitamab + lenalidomide + rituximab for the treatment of adult patients with R/R FL after ≥1 prior line of systemic therapy, based on results from the phase III inMIND trial. Read more: https://loom.ly/w2-UR0U #Lymphoma #lymsm #MedNews #MedEd
Catch up on the latest developments in Hodgkin lymphoma and T-cell lymphoma from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/wivNprc #lymsm #leusm #MedicalCongress
